The fast-casual salad chain's stock fell sharply this week, pressured by a broader retreat in growth stocks and a reiterated sell call from Goldman Sachs, despite positive signals from the broader restaurant sector.
Michigan's Attorney General has formally demanded the return of state funds from Gotion Inc., a Chinese battery manufacturer, following the collapse of its planned $2.4 billion facility. The move highlights growing tensions over foreign investment in U.S. strategic industries.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
The U.S. Federal Trade Commission has issued warnings to 42 prominent law firms, suggesting their diversity, equity, and inclusion hiring initiatives could violate antitrust laws by potentially restricting competition for talent.
Global agribusiness leader Bunge Ltd. (BG) reached a fresh three-year high this week, buoyed by strong technical indicators and sustained momentum in the essential food supply chain sector, even as analyst price targets remain widely dispersed.
Amazon is set to eliminate 16,000 corporate roles, marking its largest workforce reduction since 2023. As the tech giant streamlines operations and doubles down on AI, investors are weighing the long-term strategy against near-term turbulence.
Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.
Shares of restaurant operator Bloomin' Brands have tumbled over 35% in six months, raising questions about its financial health and growth trajectory as analysts flag significant risks.
Despite a 39% surge in six months, Darling Ingredients faces scrutiny over its long-term sales decline, margin pressures, and falling profitability. Analysts point investors toward more resilient sectors.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.
Campbell Soup Company will shutter its Hyannis, Massachusetts facility, the original home of Cape Cod Potato Chips, citing economic inefficiency. The closure, affecting 49 jobs, marks a strategic shift of production to larger plants as the snack giant consolidates its network.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
While mid-cap companies often represent a sweet spot between growth and stability, heightened competition and shifting market dynamics are putting pressure on some notable names. Here’s a closer look at three stocks where caution may be warranted.
While small-cap stocks can offer unique growth opportunities away from Wall Street's spotlight, their inherent risks demand careful scrutiny. We examine three companies where valuation concerns and competitive pressures suggest caution may be warranted.
Profitability is a crucial starting point for investors, but it's not a guaranteed shield against market shifts. As competition evolves, today's cash generators can become tomorrow's laggards. We analyze three companies with strong margins to separate resilient growth from potential stagnation.
While the allure of finding the next undervalued gem is strong, some stocks trading at low multiples may be cheap for a reason. We examine three companies where fundamental challenges could outweigh their seemingly attractive valuations.
